Lv51
1510 积分 2023-07-05 加入
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
50分钟前
已完结
IMPROVED PROGRESSION-FREE SURVIVAL WITH COMBINATION BEVACIZUMAB AND MIRVETUXIMAB SORAVTANSINE-GYNX IN PLATINUM-RESISTANT OVARIAN CANCER
18天前
已关闭
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
For insights into the real world, consider real-world data
4个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
5个月前
已关闭
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial
5个月前
已完结
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
5个月前
已完结
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
5个月前
已完结
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
5个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
5个月前
已完结
皖公网安备34019202002308
